Lodestar Investment Counsel Has Increased Illinois Tool Works (ITW) Position; NeoGenomics, Inc. (NEO) Had 9 Bullish Analysts

Lodestar Investment Counsel Llc increased Illinois Tool Works Inc. (ITW) stake by 46.01% reported in 2017Q3 SEC filing. Lodestar Investment Counsel Llc acquired 45,791 shares as Illinois Tool Works Inc. (ITW)’s stock rose 5.13%. The Lodestar Investment Counsel Llc holds 145,321 shares with $21.50 million value, up from 99,530 last quarter. Illinois Tool Works Inc. now has $59.87 billion valuation. The stock increased 0.58% or $1 during the last trading session, reaching $174.76. About 1.54M shares traded or 31.07% up from the average. Illinois Tool Works Inc. (NYSE:ITW) has risen 33.32% since January 26, 2017 and is uptrending. It has outperformed by 16.62% the S&P500.

Among 11 analysts covering NeoGenomics (NASDAQ:NEO), 9 have Buy rating, 1 Sell and 1 Hold. Therefore 82% are positive. NeoGenomics had 17 analyst reports since September 3, 2015 according to SRatingsIntel. Benchmark initiated NeoGenomics, Inc. (NASDAQ:NEO) rating on Friday, March 11. Benchmark has “Buy” rating and $8 target. The rating was downgraded by BTIG Research on Monday, September 11 to “Neutral”. First Analysis initiated the stock with “Overweight” rating in Tuesday, October 4 report. The rating was downgraded by Axiom Capital to “Sell” on Wednesday, November 16. Cantor Fitzgerald maintained NeoGenomics, Inc. (NASDAQ:NEO) on Friday, May 26 with “Buy” rating. Roth Capital maintained the shares of NEO in report on Thursday, September 3 with “Buy” rating. BTIG Research downgraded NeoGenomics, Inc. (NASDAQ:NEO) on Wednesday, July 27 to “Neutral” rating. The company was reinitiated on Wednesday, May 11 by Roth Capital. The rating was reinitiated by TH Capital with “Buy” on Monday, October 26. The stock of NeoGenomics, Inc. (NASDAQ:NEO) earned “Outperform” rating by William Blair on Sunday, September 6. See NeoGenomics, Inc. (NASDAQ:NEO) latest ratings:

26/10/2017 Broker: Janney Capital Rating: Buy
11/09/2017 Broker: BTIG Research Old Rating: Buy New Rating: Neutral Downgrade
24/08/2017 Broker: Gabelli Rating: Buy Initiates Coverage On

Investors sentiment increased to 0.87 in 2017 Q3. Its up 0.17, from 0.7 in 2017Q2. It improved, as 47 investors sold ITW shares while 354 reduced holdings. 79 funds opened positions while 268 raised stakes. 251.79 million shares or 0.92% less from 254.13 million shares in 2017Q2 were reported. Moreover, Bbva Compass National Bank has 0.26% invested in Illinois Tool Works Inc. (NYSE:ITW) for 27,325 shares. Tiverton Asset Mgmt Llc accumulated 68,822 shares or 0.58% of the stock. First Personal Serv reported 0.07% of its portfolio in Illinois Tool Works Inc. (NYSE:ITW). Pictet & Cie (Europe) Sa has 0.16% invested in Illinois Tool Works Inc. (NYSE:ITW). Thompson Siegel Walmsley Ltd Liability Com, Virginia-based fund reported 505 shares. Glob X Management Ltd Liability Corp reported 3,239 shares. Hbk Sorce Advisory Ltd accumulated 1,383 shares. 126,200 are owned by Schwartz Counsel. Commercial Bank Of Hawaii has invested 0.32% of its portfolio in Illinois Tool Works Inc. (NYSE:ITW). Ent Financial Corporation reported 5,072 shares. Rampart Mngmt Co Limited Com accumulated 0.19% or 3,830 shares. Janney Montgomery Scott Ltd Liability Com owns 60,377 shares. Washington Tru National Bank & Trust has 966 shares for 0.02% of their portfolio. Waldron Ltd Partnership owns 2,511 shares for 0.1% of their portfolio. 3,054 were reported by Woodmont Inv Counsel Limited Company.

Among 19 analysts covering Illinois Tool Works Inc (NYSE:ITW), 8 have Buy rating, 0 Sell and 11 Hold. Therefore 42% are positive. Illinois Tool Works Inc has $210.0 highest and $85 lowest target. $167.32’s average target is -4.26% below currents $174.76 stock price. Illinois Tool Works Inc had 83 analyst reports since July 24, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Monday, September 11 by Jefferies. The firm has “Buy” rating given on Thursday, January 25 by Citigroup. The stock has “Equal-Weight” rating by Morgan Stanley on Tuesday, July 25. The stock has “Hold” rating by Stifel Nicolaus on Monday, October 23. RBC Capital Markets maintained the stock with “Hold” rating in Friday, October 20 report. The firm earned “Hold” rating on Wednesday, January 24 by BMO Capital Markets. The stock has “Hold” rating by J.P. Morgan on Tuesday, October 10. Deutsche Bank maintained the shares of ITW in report on Tuesday, August 25 with “Buy” rating. The firm earned “Hold” rating on Tuesday, January 16 by Stifel Nicolaus. The company was upgraded on Thursday, June 1 by Goldman Sachs.

Since October 2, 2017, it had 0 insider purchases, and 5 insider sales for $24.79 million activity. MARTINDALE STEVEN L sold $10.19 million worth of Illinois Tool Works Inc. (NYSE:ITW) on Wednesday, October 25. SMITH HAROLD B also sold $4.99 million worth of Illinois Tool Works Inc. (NYSE:ITW) shares. Shares for $979,950 were sold by Hartnett John R.. VALLS JUAN sold $7.62M worth of Illinois Tool Works Inc. (NYSE:ITW) on Wednesday, October 25.

NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company has market cap of $632.02 million. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. It currently has negative earnings. The firm also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clientsÂ’ oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: